# Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

Study · id `cardio:ct-nct04236609` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04236609](<https://clinicaltrials.gov/study/NCT04236609>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04236609

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3050 participants.

## Technical summary

Registry record NCT04236609. Randomized; double masking; primary purpose other. Start 2020-06-15 (actual); primary completion 2023-11-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose other
- Phase: Not applicable
- Enrolled: 3050 participants (enrolled count; ClinicalTrials.gov record NCT04236609, source copy `cardio:ctgov-nct04236609-2026-10-26`, retrieved 2026-10-31)
- Started: 2020-06-15 (actual) (ClinicalTrials.gov record NCT04236609, source copy `cardio:ctgov-nct04236609-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2023-11-30 (actual) (ClinicalTrials.gov record NCT04236609, source copy `cardio:ctgov-nct04236609-2026-10-26`, retrieved 2026-10-31)
- Completion: 2024-11-30 (actual) (ClinicalTrials.gov record NCT04236609, source copy `cardio:ctgov-nct04236609-2026-10-26`, retrieved 2026-10-31)
- Countries: Australia; Austria; Bangladesh; Belgium; Brazil; Czechia; France; Germany; India; Ireland; Italy; Malaysia; Mexico; Netherlands; Poland; Singapore; South Korea; Sweden; Switzerland; Taiwan; United Kingdom (ClinicalTrials.gov record NCT04236609, source copy `cardio:ctgov-nct04236609-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04236609-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global
- Acronym: ABILITY
- Condition: Diabetes
- Condition: Coronary Artery Disease
- Condition: Acute Coronary Syndrome
- Intervention (Device): Abluminus DES+ Sirolimus Eluting Stent System (SES)
- Intervention (Device): XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)
- Lead sponsor: Concept Medical Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Concept Medical Inc. (`cardio:org-concept-medical-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial (`cardio:pubmed-41520674`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ba56b7e8e3dd9987d07f2f8ce0d07ca9f5dcfd8492c0ed6c0eb47d773869680f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
